Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of NAD Oxidase Modulation Agent QRX3 for Prevention and Treatment of Progressive Chronic Kidney Disease

NCT06866236 is registered in ClinicalTrials.gov with Ebima Clifford Okundaye as lead sponsor.

NCT NCT06866236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06866236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of NAD Oxidase Modulation Agent QRX3 for Prevention and Treatment of Progressive Chronic Kidney Disease
Lead sponsor
Ebima Clifford Okundaye
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
October 31, 2025
Completion date
July 31, 2027
Enrollment
3,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury, chronic kidney diseases, kidney failure